Cryoport partnering with the Cell and Gene Therapy Catapult in the U.K.

Cryoport and the Cell and Gene Therapy Catapult, an independent innovation and technology organisation specializing in the advancement of cell and gene therapies, announced the organisations have entered into a new strategic partnership to support the advancement of cell and gene therapies. Through this collaboration, Cryoport Systems will establish its first global supply chain logistics centre in the U.K., a Good Manufacturing Practice-compliant facility located within the bioscience cluster in Stevenage, U.K., at the CGT Catapult’s large-scale cell and gene therapy Stevenage Manufacturing Innovation Centre. The partnership will provide CGT Catapult collaborators, and the larger U.K. cell and gene therapy community, with access to Cryoport’s integrated, end-to-end supply chain capabilities including risk mitigation services and logistics support. The collaboration between the partners will commence operations in early 2024.